- Bristol-Myers Squibb Co.
- Avadel Pharmaceuticals PLC
- QDose Ltd.
- Novo Nordisk AS
- Eli Lilly & Co.
- Aventis SA
- Emisphere Technologies Inc.
- Generex Biotechnology Corp.
- Nobex Corp.
- Spherix Inc.
- GlaxoSmithKline PLC
- Pfizer Inc.
- Nektar Therapeutics
- MicroDose Therapeutx Inc.
- Quadrant Technologies Ltd.
- Quadrant Drug Delivery Ltd.
- ImClone Systems Inc.
- Amylin Pharmaceuticals Inc.
- Flamel Technologies licenses BMS diabetes drug; terminated
- BMS, QDose end inhaled insulin product deal
- Nobex, GSK sign $283mm oral insulin deal; cancelled
- Generex, Lilly enter oral insulin deal; ended
- Inhale, Pfizer end inhaled insulin deal
- Hoechst, Pfizer co-manufacture, -develop, -promote insulin
- MicroDose, Quadrant JV to develop insulin delivery system
- BMS and ImClone Systems market cancer drug; concluded
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.